The Institut Curie in France has announced the introduction of stereotactic radiotherapy as a new treatment option for localized prostate cancer in non-operated patients. This treatment requires only five sessions, significantly reducing the 33 to 37 sessions needed for conventional radiotherapy. This development was presented on October 30, 2026, during the month of awareness for male cancers.

The new treatment schedule involves five sessions over two weeks, with one session every other day. In contrast, traditional radiotherapy requires patients to attend sessions from Monday to Friday for six and a half to seven and a half weeks. The stereotactic technique delivers high doses of radiation with great precision, preserving healthy tissues around the prostate.

According to the Institut Curie, the effectiveness of stereotactic radiotherapy is comparable to that of conventional radiotherapy, with similar toxicity levels. However, no specific data was provided to support these claims. The institute plans to deploy this technique by 2027 for patients with localized, non-operated prostate cancer, which accounts for over 80% of cases at diagnosis.

The Institut Curie has 15 treatment rooms across Paris, Saint-Cloud, and Orsay, conducting over 97,000 radiotherapy sessions annually. For patients who have undergone surgery, the disease can recur in 10 to 50% of cases within ten years. In such cases, salvage radiotherapy can lead to survival without recurrence in 75 to 85% of cases, sometimes combined with six months of hormone therapy.

To determine if five sessions are sufficient for patients who have undergone surgery and are experiencing recurrence, the Institut Curie is preparing the HyPORT-01 trial. This randomized trial will compare 33 conventional sessions with five stereotactic sessions in 450 patients across 35 French centers over three years, with an expected start in the second half of 2027.

The trial's coordinator, Dr. Gilles Créhange, expects significant benefits for patients, including improved quality of life and substantial medico-economic impacts. The study aims to provide evidence for the use of stereotactic radiotherapy in patients with recurrent prostate cancer after surgery. Prostate cancer remains the most common male cancer in France, with nearly 60,000 cases reported in 2018.

The introduction of stereotactic radiotherapy offers new hope for prostate cancer patients. With its precision and reduced treatment duration, this option has the potential to greatly improve patient outcomes and experience. As the Institut Curie continues to develop and refine this treatment, patients can look forward to more effective and efficient care.

Key points

  • The Institut Curie will start offering stereotactic radiotherapy by 2027 for patients with localized, non-operated prostate cancer.
  • The HyPORT-01 trial will compare conventional and stereotactic radiotherapy in patients with recurrent prostate cancer after surgery.
  • Prostate cancer is the most common male cancer in France, with nearly 60,000 cases reported in 2018.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.